WEX says data analysis continues in phase 2b/3 study of Tectin to treat cancer pain

By Lisa Kerner

Charlotte, N.C., July 6 - WEX Pharmaceuticals Inc. said it is progressing with the detailed analysis of its phase 2b/3 data collected during the double-blind, randomized, placebo controlled study of Tectin in inadequately controlled moderate to severe cancer pain.

Analysis is complete of data from the neuropathic pain scale, McGill Pain Questionnaire and quality of life items (general activity, walking, mood, sleep), none of which were examined by the Data Monitoring Committee.

WEX said preliminary results are consistent with the results observed in its phase 2a open label study.

Vancouver, B.C.-based WEX discovers, develops, manufactures and commercializes drug products to treat pain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.